-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LNS-8801 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LNS-8801 in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LNS-8801 in Melanoma Drug Details: LNS-8801 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabozantinib S-malate in Carcinoid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Carcinoid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabozantinib S-malate in Carcinoid Tumor Drug Details: Cabozantinib s-malate (XL184,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ivosidenib in Chondrosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivosidenib in Chondrosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivosidenib in Chondrosarcoma Drug Details: Ivosidenib (Tibsovo / AG-120) acts as an...
-
Product Insights
Gastritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastritis - Drugs In Development, 2023’, provides an overview of the Gastritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OST-122 in Ulcerative Colitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.OST-122 in Ulcerative Colitis Drug Details:OST-122 is under development for the treatment of inflammatory bowel disease,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Calpurbatug in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Calpurbatug in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Calpurbatug in Methicillin-Resistant Staphylococcus aureus (MRSA) InfectionsDrug Details:calpurbatug is under development...
-
Track & Monitor
Venture Capital Investments Q3 2023
GlobalData's Venture Capital Investments report provides detailed coverage of the global venture capital investment activity across sectors in Q3 2023, covering key insights and trends.
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Products Market Report Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment...
-
Product Insights
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. The Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline drugs market research report provides comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – OST-122
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry OST-122 Drug Details OST-122 is under development for the treatment of inflammatory bowel disease,...